Literature DB >> 17090364

Clinical inquiries. What is the role of combination therapy (insulin plus oral medication) in type 2 diabetes?

Staci Eskesen1, Gary Kelsberg, Kristin Hitchcock, Vincent Lo.   

Abstract

Combination therapy using insulin plus metformin (Glucophage), a sulfonylurea, or both produces glycemic control comparable with using insulin alone, but there is less weight gain when metformin is used (strength of recommendation [SOR]: B, based on systematic review of randomized controlled trials [RCTs] with some heterogeneity). Combination therapy using insulin and pioglitazone (Actos) reduces glycosylated hemoglobin (Hb A1c) more than either insulin alone or adding pioglitazone to a sulfonylurea, but results in more weight gain (SOR: A, based on RCT). Using insulin glargine (Lantus) in combination therapy produces fewer nocturnal hypoglycemic events than using neutral protamine Hagedorn (NPH) insulin, while producing equivalent Hb A1c reduction (SOR: B, based on RCT). When the HbA1c is high (above 9.0% to 9.5%) on 1 or 2 oral agents, beginning combination therapy is more effective than adding another oral agent (SOR: B, based on subpopulation analysis in RCTs).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17090364

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  2 in total

1.  Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.

Authors:  Yasuo Terauchi; Masahiro Tamura; Masayuki Senda; Ryoji Gunji; Kohei Kaku
Journal:  Diabetes Obes Metab       Date:  2017-07-13       Impact factor: 6.577

2.  Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.

Authors:  Caroline Reilhac; Julie Dubourg; Carole Thang; Jean-Marie Grouin; Pascale Fouqueray; Hirotaka Watada
Journal:  Diabetes Obes Metab       Date:  2022-02-08       Impact factor: 6.408

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.